Market Place
Sourcing Support
Vertex Rushes FDA Filing on Strong Phase 3 Kidney Data
10 Mar 2026 //
PRESS RELEASE
Vertex Presents JOURNAVX Data on Effective Pain Management
05 Mar 2026 //
PHARMIWEB
New Painkillers Key to Combating Opioid and Pain Crisis
26 Feb 2026 //
BIOSPACE
Vertex`s Journavx Painkiller Surpasses 500K Prescriptions
13 Feb 2026 //
BIOSPACE
Vertex Sets Lofty $500M Revenue Goal For New Products In `26
13 Feb 2026 //
FIERCE PHARMA
Vertex Presents New Data on Casgevy, Children Ages 5-11 Years
06 Dec 2025 //
PHARMIWEB
Vertex Present Povetacicept Data For IGA Nephropathy At ASN
08 Nov 2025 //
BUSINESSWIRE
Vertex Shares New CF Data Including Alyftrek at NACFC 2025
23 Oct 2025 //
BUSINESSWIRE
Vertex Advances Povetacicept Program, Reveals New Data At ASN
17 Oct 2025 //
PHARMIWEB
Vertex Announces Key Advancements Across Kidney Portfolio
25 Sep 2025 //
BUSINESSWIRE
Vertex Secures CASGEVY Reimbursement for Beta Thalassemia
18 Sep 2025 //
PHARMAWEB
Vertex, Enlaza Declare War on Autoimmune Disease in $2B+ Pact
03 Sep 2025 //
BIOSPACE
Maze, Vertex Marketing Spat Escalates to Federal Regulators
28 Aug 2025 //
FIERCE PHARMA
Ono Pharma & Vertex to Develop Povetacicept in Japan, South Korea
24 Jun 2025 //
BUSINESSWIRE
Vertex`s Diabetes Therapy Allows 10 Patients to Come Off Insulin
23 Jun 2025 //
ENDPNTS
Vertex to Participate in Upcoming Investor Conferences
15 May 2025 //
BUSINESSWIRE
Vertex takes $379M hit tied to cancelled islet cell program
07 May 2025 //
FIERCE BIOTECH
Vertex discontinues AAV research for gene therapies
03 May 2025 //
FIERCE BIOTECH
ToolGen Files Patent Infringement Lawsuit Against Vertex in UK
21 Apr 2025 //
PR NEWSWIRE
Vertex`s proposed fertility support program shot down in court
01 Apr 2025 //
FIERCE PHARMA
Vertex Announces Program Updates for Type 1 Diabetes Portfolio
28 Mar 2025 //
BUSINESSWIRE
Sionna’s NBD1 Stabilisers May Differ From Vertex’s CF Treatment
02 Mar 2025 //
EXPRESSPHARMA
Vertex axes Verve gene editing pact amid shift in R&D priorities
28 Feb 2025 //
FIERCE BIOTECH
Vertex Secures CASGEVY Reimbursement For Sickle Cell In England
30 Jan 2025 //
BUSINESSWIRE
Orna, Vertex Partner On SCD And TDT Next-Gen Therapies
07 Jan 2025 //
PR NEWSWIRE
Vertex, Saudi Arabia ink MoU to boost gene therapy production
12 Dec 2024 //
FIERCE PHARMA
Vertex Presents Long-Term Data On Casgevy at ASH Annual Meeting
08 Dec 2024 //
BUSINESSWIRE
Orsini Distributes CASGEVY® Gene-Editing Therapy
14 Nov 2024 //
PR NEWSWIRE
Editas cashes in on Vertex Cas9 licensing agreement for $57M
04 Oct 2024 //
FIERCE BIOTECH
Vertex-CRISPR & Bluebird Begin Sickle Cell Gene Therapies
18 Sep 2024 //
BIOSPACE
UK`s NHS To Roll Out Vertex/CRISPR Gene Therapy For Rare Blood Disorder
08 Aug 2024 //
REUTERS
Long-term data shows durability of Vertex`s gene therapy Casgevy
14 Jun 2024 //
FIERCE PHARMA
Tessera unveils promising in vivo gene editing for sickle cell in #ASGCT24
10 May 2024 //
ENDPTS
With 64 centers activated, bluebird is ready to grow Lyfgenia
09 May 2024 //
FIERCE PHARMA
Vertex touts Casgevy sickle cell launch as bluebird makes progress Lyfgenia
06 May 2024 //
ENDPTS
Vertex licenses TreeFrog’s tech to upscale cell therapy Mfg for diabetes
23 Apr 2024 //
PRESS RELEASE
The $100 billion club gets a shakeup, driven by biotech’s new blue-chip names
20 Feb 2024 //
ENDPTS
US FDA approves Vertex/CRISPR gene therapy for an inherited blood disorder
17 Jan 2024 //
REUTERS
Saudi Arabia approves first CRISPR/Cas9 gene-edited therapy
12 Jan 2024 //
BIOSPECTRUM ASIA
Vertex cuts ties to CRISPR’s type 1 diabetes stem cell therapy
08 Jan 2024 //
FIERCE BIOTECH
Vertex pauses diabetes cell therapy trial after 2 deaths
07 Jan 2024 //
FIERCE BIOTECH
High-profile Casgevy launch could face supply hitches: doctor
21 Dec 2023 //
FIERCE PHARMA
Charles River hits milestone on quest to manufacture Casgevy
18 Dec 2023 //
FIERCE PHARMA
Europe lines up first CRISPR therapy approval
15 Dec 2023 //
ENDPTS
Vertex pays Editas $100M to use gene-editing tech
13 Dec 2023 //
FIERCE BIOTECH
FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease
09 Dec 2023 //
PR NEWSWIRE
Vertex/CRISPR selects RoslinCT as CDMO for Casgevy
29 Nov 2023 //
BIOPROCESS INTERNATIONAL
RoslinCT to manufacture exagamglogene autotemcel (exa-cel)
28 Nov 2023 //
GLOBENEWSWIRE
CRISPR Therapeutics laid off staff a week after positive AdComm
22 Nov 2023 //
FIERCE BIOTECH
Vertex and CRISPR Therapeutics Announce Authorization of CASGEVY
16 Nov 2023 //
BUSINESSWIRE
Vertex forecasts `foundational year` for CRISPR gene therapy
07 Nov 2023 //
FIERCE PHARMA
Vertex`s pricing won`t affect bluebird`s strategy on lovo-cel
07 Nov 2023 //
FIERCE PHARMA
Vertex to Present New Data on Exagamglogene Autotemcel
02 Nov 2023 //
BUSINESSWIRE
Vertex doesn’t need to do more testing for rogue gene edits
01 Nov 2023 //
ENDPTS
FDA panel says Vertex/CRISPR to assess safety risks of gene therapy
31 Oct 2023 //
REUTERS
CRISPR-Vertex gene editing 1st gets narrow review by FDA panel
28 Oct 2023 //
FIERCE BIOTECH
CRISPR on hunt for pipeline partners and enticing delivery tech
19 Oct 2023 //
FIERCE BIOTECH
Vertex Presents Positive, Updated VX-880 Results From Ongoing Phase 1/2 Study
03 Oct 2023 //
BUSINESSWIRE
U.S. watchdog lifts price estimate for Bluebird, Vertex gene therapies to $2.1 million
13 Jul 2023 //
REUTERS
Vertex and Lonza team up on new cell therapy production plant
26 Jun 2023 //
FIERCE BIOTECH
